DirectorInstitute of Haematology, Royal Prince Alfred Hospital, Sydney, AustraliaSydney, New South Wales, Australia
OC 01.4 - Interim analysis of joint outcomes in adult and adolescent patients with severe hemophilia A receiving efanesoctocog alfa during the phase 3 XTEND-ed long-term extension study
Saturday, June 22, 202413:45 – 14:00 ICT
OC 14.1 - Perioperative management with efanesoctocog alfa in adults, adolescents, and children with severe hemophilia A in the phase 3 XTEND clinical program
Sunday, June 23, 202409:30 – 09:45 ICT
PB0232 - Measuring FVIII inhibitors in samples containing emicizumab: results of a multi-laboratory field study
Sunday, June 23, 202413:45 – 14:45 ICT
